Teleflex (NYSE:TFX) today announced it received National Medical Products Administration (NMPA) approval for its UroLift system in China to treat benign prostatic hyperplasia (BPH).
Wayne, Pennsylvania-based Teleflex designed UroLift as a minimally invasive treatment option for lower urinary tract symptoms due to BPH and is indicated in the U.S. for the treatment of an enlarged prostate up to 100cc in men 45 years or older. The approval in China indicates the device for the improvement of symptoms due to urinary outflow obstruction secondary to BPH in men 50 years of age or older, according to the company.
“China is another milestone in our overseas expansion strategy for the UroLift system and provides healthcare practitioners in that region more options for treating men suffering from BPH. As a key component of our durable growth strategy, Teleflex remains committed to making the UroLift system the standard of care in the treatment of BPH globally,” CEO Liam Kelly said in a news release.
Treatment using the UroLift system can be performed as a same-day outpatient procedure for lasting relief of symptoms with minimal downtime for patients.
“Launching the UroLift system in China and offering new treatment options for patients with BPH is exciting. We are pleased to be able to bring this novel treatment option to the over 25 million men diagnosed with BPH in China,” said Ben Cheung, managing director in China for Teleflex.
Teleflex plans to seek commercialization of the product in China in the fourth quarter of 2022.
